BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37925946)

  • 1. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study.
    Chen QJ; Lin KY; Lin ZW; Zhang B; Liu MQ; Zhang JX; Huang QZ; Lin KC; Zhang JY; Wei FQ; You PH; You S; Jiang YB; Zhang H; Cheng ZQ; Wang CR; Zeng YY
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111098. PubMed ID: 37925946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
    He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
    Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
    Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y
    Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
    Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
    Front Immunol; 2022; 13():892618. PubMed ID: 35711409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
    An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X; Qin P; Wang Y; Zhang M; Cui H; Gao Q; Wang Z
    Cancer Immunol Immunother; 2023 Feb; 72(2):385-395. PubMed ID: 35907016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
    Hu X; Li R; Li Q; Zang M; Yuan G; Chen J
    BMC Infect Dis; 2022 Jul; 22(1):614. PubMed ID: 35836207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
    Choi WM; Kim GA; Choi J; Han S; Lim YS
    J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection.
    Chen JL; Lin XJ; Zhou Q; Shi M; Li SP; Lao XM
    Chin J Cancer; 2016 Mar; 35():28. PubMed ID: 26992891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load.
    Sohn W; Paik YH; Cho JY; Ahn JM; Choi GS; Kim JM; Kwon CH; Joh JW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Viral Hepat; 2015 Jun; 22(6):539-50. PubMed ID: 25377516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
    Huang G; Lai EC; Lau WY; Zhou WP; Shen F; Pan ZY; Fu SY; Wu MC
    Ann Surg; 2013 Mar; 257(3):490-505. PubMed ID: 22868358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
    Li C; Li ZC; Ma L; Li LQ; Zhong JH; Xiang BD; Gong WF
    Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):749-756. PubMed ID: 32552297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of programmed death receptor-1 antibody in patients with hepatitis B-associated liver cancer].
    Yu YY; Wang SY; Tu B; Shen YJ; Qiu Q; Luan JQ; Wang FS; Meng FP; Shi M
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):659-665. PubMed ID: 34371536
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
    Chang JI; Sinn DH; Cho H; Kim S; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2022 Sep; 67(9):4565-4573. PubMed ID: 34800218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
    Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
    World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
    Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.
    Huang X; Yan M; Deng Z; Yao L; Han D; Sun L
    BMC Gastroenterol; 2022 Nov; 22(1):452. PubMed ID: 36352372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.
    Li J; Dong XQ; Cao LH; Zhang ZQ; Zhao WF; Shang QH; Zhang DZ; Ma AL; Xie Q; Gui HL; Zhang G; Liu YX; Shang J; Xie SB; Liu YQ; Zhang C; Wang GQ; Zhao H;
    Front Cell Infect Microbiol; 2023; 13():1151899. PubMed ID: 37396307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
    Yang Y; Wen F; Li J; Zhang P; Yan W; Hao P; Xia F; Bi F; Li Q
    Liver Int; 2015 Sep; 35(9):2147-54. PubMed ID: 25676812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Kim GA; Han S; Choi GH; Choi J; Lim YS
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study.
    Sun F; Liu Z; Wang B
    BMC Cancer; 2021 Oct; 21(1):1103. PubMed ID: 34649509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.